{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T19:38:33Z","timestamp":1788550713653,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T00:00:00Z","timestamp":1620172800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T00:00:00Z","timestamp":1620172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Sampson et al. developed a novel method to estimate very low-density lipoprotein cholesterol (VLDL-C) and low-density lipoprotein cholesterol (LDL-C) in the setting of hypertriglyceridemia. Familial Combined Hyperlipidemia (FCHL) is a common primary dyslipidemia in which lipoprotein composition interferes with LDL-C estimation. This study aimed to evaluate performance of LDL-C using this new method (LDL-S) compared with LDL-C estimated by Friedewald\u2019s and Martin eq. (LDL-F, LDL-M) in FCHL.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data were collected from 340 subjects with confirmed FCHL. Concordance for VLDL-C measured by ultracentrifugation and LDL-C estimated using these measures compared to Sampson\u2019s, Martin\u2019s and Friedewald\u2019s equations was performed using correlation coefficients, root mean squared error (RMSE) and bias. Also, concordance of misclassified metrics according to LDL-C (&lt;\u200970 and\u2009&lt;\u2009100\u2009mg\/dL) and Apo B (&lt;\u200980 and\u2009&lt;\u200965\u2009mg\/dL) thresholds were assessed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Sampson\u2019s equation was more accurate (RMSE 11.21\u2009mg\/dL; R<jats:sup>2<\/jats:sup>\u00a0=\u20090.88) compared to Martin\u2019s (RMSE 13.15\u2009mg\/dL; R<jats:sup>2<\/jats:sup>\u00a0=\u20090.875) and the Friedewald\u2019s equation (RMSE 13.7\u2009mg\/dL; R<jats:sup>2<\/jats:sup>\u00a0=\u20090.869). When assessing performance according to LDL-C, Sampson\u2019s had highest correlation and lowest RMSE compared to other equations (RMSE 19.99\u2009mg\/dL; R<jats:sup>2<\/jats:sup>\u00a0=\u20090.840). Comparing performance strength across triglyceride levels, Sampson\u2019s showed consistently improved correlations compared to Martin\u2019s and Friedewald\u2019s formulas for increasing triglycerides and for the FCHL phenotype of mixed dyslipidemia. Sampson\u2019s also had improved concordance with treatment goals.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In FCHL, VLDL-C and LDL-C estimation using Sampson\u2019s formula showed higher concordance with lipid targets assessed using VLDL-C obtained by ultracentrifugation compared with Friedewald\u2019s and Martin\u2019s equations. Implementation of Sampson\u2019s formula could improve treatment monitoring in FCHL.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12944-021-01471-3","type":"journal-article","created":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T13:03:06Z","timestamp":1620219786000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Comparative assessment of LDL-C and VLDL-C estimation in familial combined hyperlipidemia using Sampson\u2019s, Martin\u2019s and Friedewald\u2019s equations"],"prefix":"10.1186","volume":"20","author":[{"given":"Arsenio","family":"Vargas-V\u00e1zquez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar Yaxmehen","family":"Bello-Chavolla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neftali Eduardo","family":"Antonio-Villa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roopa","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivette","family":"Cruz-Bautista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8517-0241","authenticated-orcid":false,"given":"Carlos A.","family":"Aguilar-Salinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,5]]},"reference":[{"key":"1471_CR1","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111\u201388.","journal-title":"Eur Heart J"},{"key":"1471_CR2","doi-asserted-by":"publisher","first-page":"234","DOI":"10.2337\/ds18-0009","volume":"31","author":"PS Jellinger","year":"2018","unstructured":"Jellinger PS. American association of clinical endocrinologists\/american college of endocrinology management of dyslipidemia and prevention of cardiovascular disease clinical practice guidelines. Diabetes Spectr. 2018;31:234\u201345.","journal-title":"Diabetes Spectr"},{"key":"1471_CR3","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1016\/j.jacc.2007.07.045","volume":"50","author":"JO Mudd","year":"2007","unstructured":"Mudd JO, Borlaug BA, Johnston PV, et al. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease. J Am Coll Cardiol. 2007;50:1735\u201341.","journal-title":"J Am Coll Cardiol"},{"key":"1471_CR4","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1373\/clinchem.2018.287037","volume":"64","author":"MR Langlois","year":"2018","unstructured":"Langlois MR, Chapman MJ, Cobbaert C, et al. Quantifying Atherogenic lipoproteins: current and future challenges in the era of personalized medicine and very low concentrations of LDL cholesterol. A consensus Statement from EAS and EFLM. Clin Chem. 2018;64:1006\u201333.","journal-title":"Clin Chem"},{"key":"1471_CR5","first-page":"224","volume":"70","author":"OY Bello-Chavolla","year":"2018","unstructured":"Bello-Chavolla OY, Kuri-Garc\u00eda A, R\u00edos-R\u00edos M, et al. Familial combined hyperlipidemia: current knowledge, perspectives, and controversies. Rev Investig Clin. 2018;70:224\u201336.","journal-title":"Rev Investig Clin"},{"key":"1471_CR6","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1161\/hq0202.104059","volume":"22","author":"MJ Veerkamp","year":"2002","unstructured":"Veerkamp MJ, de Graaf J, Bredie SJH, Hendriks JCM, Demacker PNM, Stalenhoef AFH. Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study. Arterioscler Thromb Vasc Biol. 2002;22:274\u201382.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1471_CR7","doi-asserted-by":"publisher","unstructured":"Puig N, Mi\u00f1ambres I, Ben\u00edtez S, et al. Familial combined hyperlipidemia (FCH) patients with high triglyceride levels present with worse lipoprotein function than FCH patients with isolated hypercholesterolemia. Biomedicines. 2020;8. https:\/\/doi.org\/10.3390\/biomedicines8010006.","DOI":"10.3390\/biomedicines8010006"},{"key":"1471_CR8","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.cca.2014.08.018","volume":"438","author":"I Cruz-Bautista","year":"2015","unstructured":"Cruz-Bautista I, Mehta R, Cabiedes J, et al. Determinants of VLDL composition and apo B-containing particles in familial combined hyperlipidemia. Clin Chim Acta. 2015;438:160\u20135.","journal-title":"Clin Chim Acta"},{"key":"1471_CR9","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1001\/jama.2013.280532","volume":"310","author":"SS Martin","year":"2013","unstructured":"Martin SS, Blaha MJ, Elshazly MB, et al. Comparison of a novel method vs the Friedewald equation for estimating low-density lipoprotein cholesterol levels from the standard lipid profile. JAMA. 2013;310:2061\u20138.","journal-title":"JAMA"},{"key":"1471_CR10","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.jacc.2013.01.079","volume":"62","author":"SS Martin","year":"2013","unstructured":"Martin SS, Blaha MJ, Elshazly MB, et al. Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. J Am Coll Cardiol. 2013;62:732\u20139.","journal-title":"J Am Coll Cardiol"},{"key":"1471_CR11","doi-asserted-by":"publisher","unstructured":"Sampson M, Ling C, Sun Q, et al. A New Equation for Calculation of Low-Density Lipoprotein Cholesterol in Patients With Normolipidemia and\/or Hypertriglyceridemia. JAMA Cardiol. 2020; Published online Feb 26. https:\/\/doi.org\/10.1001\/jamacardio.2020.0013.","DOI":"10.1001\/jamacardio.2020.0013"},{"key":"1471_CR12","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1080\/10408363.2020.1745142","volume":"57","author":"CS Boot","year":"2020","unstructured":"Boot CS, Luvai A, Neely RDG. The clinical and laboratory investigation of dysbetalipoproteinemia. Crit Rev Clin Lab Sci. 2020;57:458\u201369.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"1471_CR13","unstructured":"R: The R Project for Statistical Computing. http:\/\/www.R-project.org. Accessed 11 July 2020."},{"key":"1471_CR14","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.atherosclerosis.2018.06.868","volume":"277","author":"R Mehta","year":"2018","unstructured":"Mehta R, Reyes-Rodr\u00edguez E, Bello-Chavolla OY, et al. Performance of LDL-C calculated with Martin\u2019s formula compared to the Friedewald equation in familial combined hyperlipidemia. Atherosclerosis. 2018;277:204\u201310.","journal-title":"Atherosclerosis"},{"key":"1471_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2018.11.013","volume":"280","author":"J Luijten","year":"2019","unstructured":"Luijten J, van Greevenbroek MMJ, Schaper NC, et al. Incidence of cardiovascular disease in familial combined hyperlipidemia: a 15-year follow-up study. Atherosclerosis. 2019;280:1\u20136.","journal-title":"Atherosclerosis"},{"key":"1471_CR16","doi-asserted-by":"publisher","unstructured":"Pirillo A, Norata GD, Catapano AL. Beyond LDL-C levels, does remnant cholesterol estimation matter? Eur J Prev Cardiol. 2020:27(10):1088\u201390. https:\/\/doi.org\/10.1177\/2047487319899622.","DOI":"10.1177\/2047487319899622"},{"key":"1471_CR17","doi-asserted-by":"publisher","first-page":"e0148147","DOI":"10.1371\/journal.pone.0148147","volume":"11","author":"J Lee","year":"2016","unstructured":"Lee J, Jang S, Son H. Validation of the Martin method for estimating low-density lipoprotein cholesterol levels in Korean adults: findings from the Korea National Health and nutrition examination survey, 2009-2011. PLoS One. 2016;11:e0148147.","journal-title":"PLoS One"},{"key":"1471_CR18","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1001\/jamacardio.2018.1533","volume":"3","author":"SS Martin","year":"2018","unstructured":"Martin SS, Giugliano RP, Murphy SA, et al. Comparison of low-density lipoprotein cholesterol assessment by Martin\/Hopkins estimation, Friedewald estimation, and preparative ultracentrifugation: insights from the FOURIER trial. JAMA Cardiol. 2018;3:749\u201353.","journal-title":"JAMA Cardiol"},{"issue":"6","key":"1471_CR19","first-page":"612","volume":"13","author":"D Sacks","year":"2018","unstructured":"From the American Association of Neurological Surgeons (AANS), American Society of Neuroradiology (ASNR), Cardiovascular and Interventional Radiology Society of Europe (CIRSE), Canadian Interventional Radiology Association (CIRA), Congress of Neurological Surgeons (CNS), European Society of Minimally Invasive Neurological Therapy (ESMINT), European Society of Neuroradiology (ESNR), European Stroke Organization (ESO), Society for Cardiovascular Angiography and Interventions (SCAI), Society of Interventional Radiology (SIR), Society of NeuroInterventional Surgery (SNIS), and World Stroke Organization (WSO), Sacks D, Baxter B, BCV C, Carpenter JS, Cognard C, et al. Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke. Int J Stroke. 2018;13(6):612\u201332.","journal-title":"Int J Stroke"},{"key":"1471_CR20","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1177\/2047487315569411","volume":"22","author":"MJ Pencina","year":"2015","unstructured":"Pencina MJ, D\u2019Agostino RB, Zdrojewski T, et al. Apolipoprotein B improves risk assessment of future coronary heart disease in the Framingham heart study beyond LDL-C and non-HDL-C. Eur J Prev Cardiol. 2015;22:1321\u20137.","journal-title":"Eur J Prev Cardiol"},{"key":"1471_CR21","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ijcard.2006.03.045","volume":"116","author":"W Pei","year":"2007","unstructured":"Pei W, Sun Y, Lu B, et al. Apolipoprotein B is associated with metabolic syndrome in Chinese families with familial combined hyperlipidemia, familial hypertriglyceridemia and familial hypercholesterolemia. Int J Cardiol. 2007;116:194\u2013200.","journal-title":"Int J Cardiol"},{"key":"1471_CR22","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1001\/jamacardio.2019.3780","volume":"4","author":"AD Sniderman","year":"2019","unstructured":"Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol. 2019;4:1287\u201395.","journal-title":"JAMA Cardiol"},{"key":"1471_CR23","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1161\/CIRCULATIONAHA.119.041149","volume":"140","author":"C Welsh","year":"2019","unstructured":"Welsh C, Celis-Morales CA, Brown R, et al. Comparison of conventional lipoprotein tests and apolipoproteins in the prediction of cardiovascular disease. Circulation. 2019;140:542\u201352.","journal-title":"Circulation"},{"key":"1471_CR24","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.jacc.2015.10.055","volume":"67","author":"JT Wilkins","year":"2016","unstructured":"Wilkins JT, Li RC, Sniderman A, Chan C, Lloyd-Jones DM. Discordance between Apolipoprotein B and LDL-cholesterol in young adults predicts coronary artery calcification: the CARDIA study. J Am Coll Cardiol. 2016;67:193\u2013201.","journal-title":"J Am Coll Cardiol"},{"key":"1471_CR25","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1373\/clinchem.2016.264515","volume":"63","author":"PR Lawler","year":"2017","unstructured":"Lawler PR, Akinkuolie AO, Ridker PM, et al. Discordance between circulating Atherogenic cholesterol mass and lipoprotein particle concentration in relation to future coronary events in women. Clin Chem. 2017;63:870\u20139.","journal-title":"Clin Chem"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-021-01471-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-021-01471-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-021-01471-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T13:05:11Z","timestamp":1620219911000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-021-01471-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,5]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1471"],"URL":"https:\/\/doi.org\/10.1186\/s12944-021-01471-3","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,5]]},"assertion":[{"value":"3 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The local Human Research Ethics Committee of the Instituto Nacional de Ciencias M\u00e9dicas y Nutrici\u00f3n Salvador Zubir\u00e1n approved all proceedings regarding this study and all participants provided written consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Nothing to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}